Clinical Trial

Repurposing Semaglutide for the Treatment of Cocaine Use Disorder

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), in combination with cognitive behavioral therapy (CBT) for the treatment of cocaine use disorder (CUD). This project is part of the NIH Helping to End Addiction Long-term (HEAL) initiative (https://heal.nih.gov/).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-11-10; most recent amendment 2026-03-16.
Status change: Not Yet Recruiting → Recruiting 2026-03-16
Trial Details
NCT Number NCT07227948
Lead Sponsor The University of Texas Health Science Center, Houston
Collaborators: National Institute on Drug Abuse (NIDA)
Conditions Cocaine Use Disorder
Enrollment 75 participants
Start Date 2026-01-15
Primary Completion 2029-01-28 (estimated)
Study Completion 2029-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-03-19